NEW YORK, Nov. 13, 2017 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced that Andrew Satlin M.D. has joined the company as Executive Vice President and Chief Medical Officer. Dr. Satlin brings broad experience to the Company with over 20 years of industry experience in all phases of drug development in multiple therapeutic areas, including neurology and psychiatry, as well as cardiovascular and metabolic disorders. Dr. Satlin has extensive expertise in the design and conduct of clinical trials in Alzheimer’s disease, Parkinson’s disease, epilepsy, schizophrenia, depression, anxiety, heart failure and hypertension.
Dr. Satlin spent 9 years at Eisai, most recently serving as Executive Vice-President, Global Head of Medicine Creation Strategy, Neurology Business Group. Before joining Eisai, he spent 11 years at Novartis in positions of increasing responsibility, including leadership of the Neurosciences regulatory group. Prior to joining Novartis Dr. Satlin was an Assistant Professor of Psychiatry at Harvard Medical School. Dr. Satlin was also the Director of Geriatric Psychiatry and established a dementia clinic at McLean Hospital in Massachusetts. Dr. Satlin received his medical degree from Harvard Medical School and completed his residency in psychiatry and fellowship in geriatric psychiatry at McLean Hospital. Dr. Satlin received his bachelor’s degree from Yale University.
“We are excited to welcome Dr. Satlin as we continue to expand our team. Andy is a respected industry leader who strengthens our expertise in CNS drug development, and we look forward to working together as we continue the development of lumateperone and our pipeline,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.
“I am enthusiastic about joining the team at Intra-Cellular Therapies at this important time in the development of lumateperone. I look forward to the opportunity to support its succesful registration, and to help advance a pipeline of novel compounds addressing unmet medical needs in both psychiatry and neurology,” stated Dr. Satlin.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson’s and Alzheimer’s disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer’s disease, depression and other neuropsychiatric and neurological disorders. Lumateperone, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer’s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company’s PDE1 portfolio, ITI-214, is in development for the treatment of symptoms associated with Parkinson’s disease.
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
Burns McClellan, Inc.
Justin Jackson (Media)